SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift reports net loss of Rs 1.64 crore in Q1

16 Aug 2018 Evaluate

Ind-Swift has reported results for first quarter ended June 30, 2018.

The company has reported net loss of Rs 1.64 crore for the quarter under review as compared to net loss of Rs 14.56 crore for the same quarter in the previous year. However, total revenue of the company increased by 48.54% at Rs 80.67 crore for Q1FY19 as compared Rs 54.31 crore for the corresponding quarter previous year.

Ind-Swift manufactures and markets finished dosage forms, through their different divisions, focusing on the needs of various therapeutic segments. The divisions include the following: Super Speciality, Animal Division, Daignosis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×